Lynda Charters

Visible-light optical coherence tomography proves valuable in studies.

The American Medical Association is advocating equitable resource distribution of vaccinations to assist low-income countries.

According to investigators, infants may have an edge over adults, with babies demonstrating a stronger immune response to the SARS-CoV-2 virus.

Investigators find approach improved vision and visual fields in some patients.

Physicians are finding a wealth of information that is readily available.

Physicians are left to determine which treatments can offer patients best outcomes.

Amid pandemic, physicians and patients have embraced technology.

Update reduces complications

RGX-314 eyed by investigators as a therapeutic option for exudative AMD.

Option could prove to enhance safety for both patients and staff.

Use of such procedures increased markedly in analysis of IRIS Registry Data.

UK physician notes a full systemic work-up needed to determine source of infection.

Study results show that aflibercept-treated eyes are protected.

Study results show the device offers an effective long-term option for patients.

Virtual reality, home visual field testing offer new options for physicians.

ADVM-022 offers sharp decrease in treatment burden for patients with nAMD.

Technologies offer different approaches to different scenarios.

Intermediate/near vision improvements are achieved without compromising distance vision.

Investigators determine that patient rates of adherence with gonioscopy are low.

Patients frequently require a multidisciplinary approach.

A recent study may indicate the need for future research to assess the relationship between pain and the anterior chamber depth.

Investigators at Mount Sinai report that ocular cells may be infected directly by the virus, with the limbus especially susceptible.

Experts discuss durability of action and atrophy inhibitor among primary treatment goals.

According to investigators, understanding the ocular manifestations in patients with COVID-19 could ultimately help with the diagnosis and prevent transmission.

Mark Pennesi, MD, PhD, reports during ARVO 2021 that preliminary results have shown that AGTC-401 and AGTC-402 seem safe and well tolerated in patients with ACHM.

Investigators examine the demographic, refractive, PRO data measure.

Observation over the long term is needed to determine treatment efficacy.

Friederike Kortuem, MD, MSc, discusses how treatment with voretigene neparvovec-rzyl led to a short-term change in the foveal morphology in a patient with visual impairment that included nyctalopia and decreased visual acuity in early childhood.

Worldwide increase in technologies for ophthalmic use is dramatic.

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.